Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Minnesota: - Children's Hospitals and Clinics of Minnesota - Minneapolis — Minneapolis, Minnesota
- University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 3 Recruiting Industry
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Minnesota: - Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Minnesota: - Minnesota Oncology Hematology (MNO) ( Site 8002) — Maplewood, Minnesota
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Minnesota: - Minnesota Oncology Hematology — Minneapolis, Minnesota
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in Minnesota: - Minnesota Oncology Hematology PA — Minneapolis, Minnesota
Phase 3 Recruiting Industry
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Sponsor: Imunon
NCT ID: NCT06915025
Sites in Minnesota: - Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Minnesota: - Mercy Hospital — Coon Rapids, Minnesota
- Essentia Health - Deer River Clinic — Deer River, Minnesota
- Essentia Health Cancer Center — Duluth, Minnesota
- Miller-Dwan Hospital — Duluth, Minnesota
- Fairview Southdale Hospital — Edina, Minnesota
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Minnesota: - University of Minnesota - Minneapolis /ID# 275718 — Minneapolis, Minnesota
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780 — Saint Louis Park, Minnesota
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Minnesota: - Minnesota Oncology Hematology — Maple Grove, Minnesota
- Mayo Clinic (Minnesota) — Rochester, Minnesota
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Minnesota: - Site 0288 - Minnesota Oncology Hematology - Maplewood — Maplewood, Minnesota
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Minnesota: - Minnesota Oncology-Minneapolis — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Minnesota: - USOR Minnesota Oncology Hematology — Maplewood, Minnesota
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Minnesota: - St. Luke's Hospital — Duluth, Minnesota
Phase 1, Phase 2 Recruiting Industry
A Study of Emi-Le in Participants with Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05377996
Sites in Minnesota: - Mayo Clinic - Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Minnesota: - University of Minnesota/Masonic Cancer Center — Minneapolis, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in Minnesota: - Minnesota Oncology Hematology, P.A. — Maple Grove, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Minnesota: - Mayo Rochester — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Minnesota: - Mayo Clinic in Rochester, Minnesota — Rochester, Minnesota
Phase 2 Recruiting Industry
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Sponsor: Corcept Therapeutics
NCT ID: NCT06906341
Sites in Minnesota: - 518 — Minneapolis, Minnesota
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Minnesota: - Health Partners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
- Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer t…
Sponsor: AbbVie
NCT ID: NCT07024784
Sites in Minnesota: - University Of Minnesota /ID# 277850 — Minneapolis, Minnesota